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Ligation of B cell receptor (BCR) on BKS-2, an imma-
ture B cell lymphoma by anti-IgM antibodies (Ab)
caused apoptosis. Here we report that signaling through
B cell receptor in wild type BKS-2 cells down-regulated
the expression of Egr-1, a zinc finger-containing tran-
scription factor. A reduction in the level of Egr-1 mRNA
could be demonstrated as early as 30 min after the liga-
tion of BCR on BKS-2 cells. Immunocytochemical and
Western blot analysis revealed that the expression of
EGR-1 protein was also inhibited by anti-IgM treatment.
Antisense oligonucleotides to Egr-1 caused growth inhi-
bition and apoptosis in BKS-2 cells, suggesting that ex-
pression of Egr-1 is important for the survival of these B
lymphoma cells. In contrast to wild type BKS-2 cells, the
mutant 1.B5 cell line, which is refractory to B cell recep-
tor-mediated growth-inhibitory signals, showed an in-
creased expression of Egr-1 upon treatment with anti-
IgM. These results implicate a role for Egr-1 in blocking
B cell receptor-mediated apoptosis in immature B cells.
During B lymphocyte development in the bone marrow, a
large number of B cells that are specific to a broad array of
antigens are generated. This repertoire of B cells also includes
a considerable proportion of B cells that recognize self-anti-
gens. Elimination of such self-reactive B cells appears to occur
at the immature B cell stage of development and is believed to
be initiated as a result of interaction between B cell receptor
(BCR)1 and self-antigens (1–3). Apoptosis represents one of the
major mechanisms by which self-reactive B cells are eliminated
during B cell development (4). In contrast to immature B cells,
engagement of the BCR induces mature B cells to proliferate
and differentiate into memory cells and antibody-producing
cells (5).
The diverse responses initiated by the BCR in the B cells of
different maturation stages do not appear to be due to differ-
ences in the architecture of the BCR itself (1–5). Consistent
with this, signaling through the BCR induces a number of early
biochemical events, such as the activation of protein-tyrosine
kinases and protein kinase C isoenzymes, which have been
found to be nearly identical in immature and mature B cells (5).
Recent studies found that the later downstream events that
affect G1/S transition, such as the activities of cyclin E and
cdk2 were increased in mature but not immature B cells (6).
Unlike these late events, thus far, very few early biochemical
changes that are unique to growth versus apoptosis response of
B cells have been identified. Expression of Egr-1, an immediate
early gene, has been reported to be increased in mature B cells
triggered via BCR to proliferate (7). Therefore, we investigated
the importance of this gene for growth and apoptosis response
of immature B cells using a lymphoma model.
The immediate early gene, Egr-1 encodes a nuclear protein
that is a prototypic member of a family of transcription factors
(8, 9). Expression of Egr-1 is rapidly induced in many cell types
by a variety of mitogens during G0-G1 transition (10–14). Egr-1
is also known as NGFI-A (13), Krox 24 (12), Zif 268 (10), TIS8
(15), and it activates transcription by high affinity binding to
the regulatory element GCG(G/T)GGGCG in a zinc-dependent
manner (8, 16, 17). The GC-rich consensus target sequence of
Egr-1 has been identified in: the promoter regions of transcrip-
tion factors such as junD and nur77 (16, 18); growth factors
such as platelet-derived growth factor, insulin-like growth fac-
tor-II, basic fibroblast growth factor, epidermal growth factor
receptor (19, 20); thymidine kinase, an enzyme that is crucial
in DNA biosynthesis (9); and cell cycle regulators such as the
retinoblastoma susceptibility gene, Rb (21), cyclin D1 (22), tu-
mor necrosis factor-a (23), and interleukin-2 (24). Recently,
EGR-1 has been shown to regulate transcription of ICAM-I and
CD44 molecules in B lymphocytes (25, 26).
Signaling through BCR induced a rapid Egr-1 expression in
mature splenic B cells, which was found to be a protein kinase
C-dependent event (7, 19, 27). Studies with Egr-1-specific an-
tisense oligonucleotides have demonstrated that induction of
Egr-1 is necessary for antigen receptor-mediated activation of
B and T lymphocytes (7, 28). However, in contrast to mature B
cells, anti-IgM stimulation failed to induce Egr-1 expression in
immature B cells (7, 29, 30). Thus, the major difference ob-
served between mature and immature B cells in response to
antigen receptor-mediated signaling appears to be the varia-
tion in expression of Egr-1. Given the fact that EGR-1 trans-
regulates several molecules involved in cell cycle and growth
(8–26, 30), its expression may have a critical role in the deter-
mination of positive versus negative growth responses in ma-
ture and immature B cells triggered with anti-IgM. Therefore,
studies were undertaken to examine the role of Egr-1 expres-
sion in anti-IgM-induced negative growth response in BKS-2,
an immature B lymphoma cell line (31–35). We have shown
previously that BKS-2 cells undergo growth inhibition and
apoptosis in response to signals transduced by BCR cross-
linking as well as by ionomycin (31, 32). This growth inhibition
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in BKS-2 cells was abrogated by T helper cell contact-mediated
signals (32). Rapamycin, a potent immunosuppressive drug,
has also been shown to cause apoptosis in BKS-2 cells (33). In
the present study, we report that BKS-2 cells constitutively
express high levels of Egr-1 mRNA, which are down-regulated
upon signaling through BCR. Blocking Egr-1 expression by
antisense oligonucleotides caused apoptosis in BKS-2 cells.
Furthermore, we demonstrate that Egr-1 mRNA expression is
up-regulated in 1.B5, a mutant BKS-2 cell line that is refrac-
tory to BCR-mediated growth inhibitory signals.
MATERIALS AND METHODS
Cell Lines—Isolation and characterization of BKS-2 lymphoma has
been described elsewhere (35). This lymphoma originated in a CBA/N
mouse transferred with spleen cells from aged CBA/Ca mice. The char-
acteristics of BKS-2 cells are similar to immature B cells in that they
express high levels of IgM but have very little or no IgD. BKS-2 cells are
monoclonal in origin and are grown in CBA/N mice or SCID mice as
splenic tumor by serial intravenous injections. These cells attain max-
imal growth (4–6 3 108) in about 7–10 days and are collected for
experimental use at this stage. BKS-2 cells from CBA/N or SCID hosts
behave similarly (31–33), and cells from the former were used in most
experiments. Depletion of host residual T cells was performed as de-
scribed previously (31).
1.B5 is one of the several clones of ethylmethanesulfonic acid-mu-
tagenized BKS-2 cells selected by their resistance to anti-IgM-induced
growth inhibition. Briefly, 40 3 106 BKS-2 lymphoma cells were treated
with 300 mg/ml ethylmethanesulfonate for 24 h. Then, the lymphoma
cells were washed and recultured for 2–3 days in IF-12 medium until
there were visible signs of growth and were subjected to selective
conditions by requiring them to grow in the presence of PMA or anti-m.
The anti-m-resistant cells were cloned by limiting dilution in 96-well
plates using T cell-derived supernatants to augment growth under low
cell density conditions. The expression of surface IgM and several other
B cell surface molecules such as class I, class II, FcR, CD19, CD22,
CD45RB, CD5, and CD72 were similar in the mutant 1.B5 and the wild
type BKS-2 cells.2 Like the wild type BKS-2, the mutant 1.B5 cells were
also susceptible to growth inhibition by rapamycin as well as
ionomycin.
Normal Splenic B Lymphocytes—Spleen cells were obtained from
8–10-week-old DBA/2 mice (Jackson Laboratory, Bar Harbor, ME). T
cells were depleted by treatment with a mixture of anti-T cell antibodies
and complement as described above. Depletion of T cells was verified by
flow cytometry and by 99% depletion of response to the T cell mitogen,
concanavalin A.
Reagents—The characteristics of the monoclonal rat anti-mouse m
chain Ab, AK11, have been described previously (34, 36). This hybri-
doma cell line obtained from Dr. R. Noelle (Dartmouth Medical School,
Hanover, NH), was grown in vitro, and the culture supernatant was
affinity-purified by passing through a column containing mouse IgM
protein (HPCM2, a hybridoma from BALB/c origin) coupled to agarose
beads (Bio-Rad) (34). AK11 monoclonal Ab was coupled to CNBr-Sepha-
rose 4B (Pharmacia) and was resuspended at a concentration of 10% in
0.85% saline (34). This suspension was used in cultures at a final
concentration of 0.5% or 1.0%. S4B6, a rat monoclonal Ab (IgG2a)
specific for IL-2, was used as a control Ab. In experiments aimed at
blocking Egr-1 expression, we used a phosphorothioate-capped anti-
sense Egr-1 oligodeoxynucleotide (59-GsCsGGGGTGCAGGGGCA-
CAsCsT-39) and a control phosphorothioate-capped nonsense oligode-
oxynucleotide (59-CsGsCCGCACCACCGCGAGTsCsA-39) purchased
from the Regional DNA Synthesis Laboratory, Calgary, Alberta, Can-
ada. The phosphorothioate oligomers 1d and 3Db containing CpG mo-
tifs described by Krieg et al. (37) were also obtained from the Regional
DNA Synthesis Laboratory. The CD72 and the Gsa-specific oligomers
were obtained from Genosys Biotechnologies (The Woodlands, TX).
Northern (RNA) Analysis—Isolation of total RNA by the guanidium
isothiocyanate-phenol-chloroform method and Northern analysis were
performed as described previously (38, 39). The probe for Egr-1 was
prepared with a 3.1-kilobase cDNA fragment from pCMV-EGR-1 (40).
Prehybridization and hybridization were done overnight at 62 °C, and
the blots were washed to a final stringency of 0.1 3 SSC (15 mM NaCl,
1.5 mM sodium citrate, pH 7.0) at 62 °C before autoradio-
graphy as described previously (41). Equal loading of RNA was
verified by probing blots with cDNA for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
Immunocytochemistry—EGR-1-positive BKS-2 cells were detected by
immunocytochemistry as described (41). Briefly, cells were exposed to
control or anti-IgM Ab for 24 or 48 h as indicated and subjected to
immunocytochemistry with anti-EGR-1 Ab (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA). Reactions with biotinylated anti-rabbit immu-
noglobulin Ab and avidin-biotin-peroxidase complexes and staining
with diaminobenzidine-H2O2 were sequentially performed as described
in the Vectastain Elite ABC kit instruction manual (Vector Laborato-
ries, Burlingame, CA). To enable black and white photography of im-
ages, counterstaining with methyl green was omitted.
Western Blot Analysis—BKS-2 cells (1 3 107/ml) were cultured with
anti-IgM Ab, AK11 (10 mg/ml) or control Ab (S4B6) for 24 h. After
stimulation, cells were pelleted, washed, and solubilized in 100 ml of
lysis buffer (1% Triton X-100, 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10
mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 2 mg/ml leupeptin, and 2 mg/ml aprotinin) on ice for 30 min.
The detergent-insoluble materials were removed by centrifugation at
12,000 3 g for 20 min at 4 °C. Protein extracts were precleared with
protein A-Sepharose beads for 1 h at 4 °C, following which anti-EGR-1
Ab (Santa Cruz) was added and further incubated for 6 h at 4 °C. The
immune complexes were collected on protein A-Sepharose beads by an
additional 4 h incubation. The beads were separated by centrifugation
and washed extensively with 1.5 M NaCl and followed by 10 mM Tris-
HCl, pH 7.5, before resuspending in SDS-PAGE sample buffer. Proteins
were separated by electrophoresis on a 10% SDS-polyacrylamide gel.
The resolved proteins were transferred onto Immobilon-P nitrocellulose
membranes (Millipore, Bedford, MA) in a buffer containing 25 mM Tris,
192 mM glycine, and 20% methanol, pH 9.0, at 90 V for 1 h. Prestained
protein standards (Bio-Rad) were included to indicate the molecular
weight range and to verify transfer of proteins. After blocking in 5%
milk powder in TBST (50 mM Tris, 200 mM NaCl, pH 7.4, 0.05% Tween
20) for 2 h, the nitrocellulose membranes were incubated with anti-
EGR-1 Ab for overnight followed by horseradish peroxidase-conjugated
goat anti-rabbit Ab (Santa Cruz, CA) for additional 2 h. The blots were
then developed with an enhanced chemiluminescence kit (NEN Life
Science Products) according to manufacturer’s instructions.
Proliferation Assay—Proliferation of cells was assessed by tritiated
thymidine uptake. Lymphoma cells (2 3 104/well) or splenic B cells (2 3
105) were cultured in 96-well flat bottom microtiter plates (Costar,
Cambridge, MA) in 0.2 ml of 1:1 mixture of Iscove’s and Ham’s F12
(IF-12) medium containing supplements and 5% heat-inactivated FCS
as described previously (31). Cultures were incubated at 37 °C with 5%
CO2 for a total of 48 h and were pulsed with 1 mCi of [
3H]thymidine
(specific activity 2 Ci/mmol; NEN Life Science Products) during the last
4-h culture period. The cultures were harvested onto glass fiber filters
using a Packard 96-well harvester, and [3H]thymidine incorpora-
tion was determined by a Matrix-96 b counter (Packard, Downers
Grove, IL).
Apoptotic Staining—BKS-2 cells were stained for apoptosis as de-
scribed previously (42, 43). Briefly, cells treated with and without
anti-IgM (5 mg/ml) for 24 or 48 h were resuspended at 1 3 106/ml in
PBS. Hoechst 33342 was added at 5 mg/ml, and the cells were incubated
in dark for 30 min at 37 °C. Excess of dye was removed by centrifuga-
tion, and cells were incubated with Merocyanine 540 (MC 540) (2 mg/ml)
for 20 min at room temperature in dark. After washing the excess of dye
in PBS, cells were analyzed by flow cytometry using a FACSTAR flow
cytometer (Becton Dickinson, CA). Gates were set to analyze cell cycle
and apoptosis stages. Hoechst 33342 is a DNA-specific dye that meas-
ures the amount of DNA, while MC540 binds to the inner membrane
phospholipids that become exposed during early stages of apoptosis.
This method of staining distinguishes five different stages of cells. They
are R1: viable resting cells, 2n DNA and MC540 dull; R2: viable cycling
cells, .2n and MC540 dull; R3: resting cells undergoing apoptosis, 2n
and MC540 bright; R4: cycling cells undergoing apoptosis, .2n and
MC540 bright; and R5: cells that moved into later stages of apoptosis as
they become Hoechst 33342 dull.
RESULTS
Signaling through BCR Inhibits Egr-1 mRNA Expression in
BKS-2 Cells—We have shown previously that signaling
through BCR using anti-IgM Ab causes apoptosis in BKS-2
lymphoma cells (31). To examine whether this signal alters the
expression of Egr-1, Northern analysis was performed using
total RNA isolated from BKS-2 cells stimulated with anti-IgM
2 Muthukkumar, S., Venkataraman, C., Woods, T., and Bondada, S.,
Mol. Immunol., in press.
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Ab for various periods of time. As shown in Fig. 1, a high level
of constitutive expression of Egr-1 was observed in BKS-2 cells
(lane 1). A strong reduction in the level of Egr-1 mRNA was
noticed as early as 30 min after exposure to anti-IgM Ab (lane
2). A continued reduction in the level of Egr-1 message was
evident in cells treated with anti-IgM Ab for 1 and 3 h. At 24 h
after anti-IgM treatment, Egr-1 expression was barely detect-
able in BKS-2 cells (lane 5). Probing for GAPDH message
demonstrated equal loading of RNA in all five lanes. These
results suggest a correlation between down-regulation of Egr-1
gene expression and the pathway leading to apoptosis in re-
sponse to signaling via BCR in BKS-2 cells.
Stimulation of BKS-2 Cells with Anti-IgM Ab Inhibits EGR-1
Protein Expression—To elucidate whether expression of EGR-1
protein is correlated with the reduction of its mRNA in anti-
IgM-treated cells, we performed immunocytochemical analysis
as a method to test the level of EGR-1 protein expression.
Additionally, we initiated studies with Egr-1-specific antisense
oligonucleotides to directly evaluate the relation between the
reduction in Egr-1 levels and anti-m-induced growth inhibition.
Immunocytochemical analysis was performed to determine the
effectiveness of the oligonucleotide treatment on the protein
expression. The BKS-2 cells were treated with control Ig, anti-
IgM Ab, nonsense, or antisense oligomers to Egr-1 for 24 h.
Then the cells were stained with anti-EGR-1 Ab as described
under “Materials and Methods.” As shown in Fig. 2 (A and C),
most of the BKS-2 cells were EGR-1-positive after nonsense
oligomer or control antibody treatment. On the other hand, a
large number of BKS-2 cells that were stimulated with anti-
IgM Ab failed to express EGR-1 (Fig. 2D), demonstrating that
the reduction in Egr-1 message seen in Fig. 1 is accompanied by
a decrease in the protein. The treatment with antisense oli-
gomers for 24 h was also effective in reducing the number of
BKS-2 cells expressing the EGR-1 protein (Fig. 2B).
To further confirm the down-regulation of EGR-1 protein in
response to signaling through BCR, we also performed Western
blot analysis on protein extracts from BKS-2 cells treated with
anti-IgM or control Ig. As shown in Fig. 3, control Ig-treated
BKS-2 cells expressed a high level of EGR-1 protein, which
corresponds to the approximate molecular weight of 82 kDa
(lane 1). In contrast, a strong reduction in the levels of EGR-1
protein was observed in the cells that were stimulated with
anti-IgM (lane 2). Densitometry analysis showed a more than
3-fold reduction in the level of EGR-1 protein in the cells that
are stimulated with anti-IgM. The integrated optical density
values for EGR-1 protein in control Ig and anti-IgM-treated
BKS-2 cells were 7.83 and 2.07, respectively. The molecular
weight of EGR-1 protein is consistent with that reported in
other cell types (8). The band seen below the EGR-1 protein is
Ig heavy chain, and its intensity was not altered by either
control Ig or anti-IgM treatment. Similar intensities of heavy
chain band in both lanes also point to the equal loading of
proteins. Together, these results clearly indicate the down-
regulation of EGR-1 protein in BKS-2 cells upon signaling
through BCR.
Antisense Egr-1 Oligomer Causes Growth Inhibition in
BKS-2 Cells—To identify whether or not the anti-IgM-induced
down-regulation of Egr-1 expression is a probable cause of
growth inhibition in BKS-2 cells, we treated them with various
concentrations of nonsense and antisense Egr-1 oligomers for
48 h. The growth response was then assessed by [3H]thymidine
incorporation. Antisense oligomer at 10 mM caused a strong
growth inhibition in BKS-2 cells (Fig. 4). A complete growth
inhibition was observed when the cells were treated with an-
tisense Egr-1 oligomer at 25 mM concentration. On the other
hand, same concentrations of nonsense oligomer did not inhibit
the cell growth. Similar results were seen when the cells were
exposed to nonsense or antisense Egr-1 oligomer for 24 h (data
not shown). The lack of growth inhibition in nonsense oligomer-
treated cultures (prepared in a manner similar to that of anti-
sense) suggests that the growth inhibitory effect caused by
antisense oligomer is not due to toxicity. These results demon-
strate that Egr-1 expression is critical for the survival of BKS-2
immature B lymphoma cells.
Since oligonucleotides can have unexpected toxic effects, a
FIG. 1. Anti-IgM stimulation inhibits Egr-1 mRNA expression
in BKS-2 cells. BKS-2 cells were stimulated with anti-IgM (10 mg/ml)
for various intervals of time as indicated. Then the cells were processed
for Northern analysis with Egr-1 or GAPDH cDNA probe. The same blot
was later analyzed for the expression of GAPDH. The times of exposure
to x-ray film for the Egr-1 blot and GAPDH blot were 24 and 6 h,
respectively. Results from one of four experiments are shown.
FIG. 2. Egr-1 antisense oligomer and anti-IgM treatment inhib-
its EGR-1 protein expression in BKS-2 cells. BKS-2 cells (1 3
106/ml) were cultured with either 10 mM nonsense or antisense oli-
gomers for 24 h. Other groups of cells were stimulated with 10 mg/ml
control Ig or anti-IgM Ab. The cells were then subjected to immuncy-
tochemistry using anti-EGR-1 Ab, as described under “Materials and
Methods.” The methyl green counterstaining was not performed in
these experiments so as to enable black-and-white photography of these
cells. EGR-1-positive cells showed a dark brown nuclear staining with
diaminobenzidine-H2O2 substrate. A and B show cells treated with
nonsense and antisense oligomers to Egr-1, respectively. Cells stimu-
lated with control Ig (C) and anti-IgM (D) are also shown. Similar
results were obtained in four other independent experiments.
FIG. 3. Stimulation with anti-IgM Ab inhibits EGR-1 protein
expression. BKS-2 cells (10 3 106) were stimulated with 10 mg/ml
anti-IgM or control Ig for 24 h. Whole cell protein extracts were pre-
pared and were then subjected to Western blot analysis for EGR-1 as
described under “Materials and Methods.” Lane 1 shows cells treated
with control Ig, and lane 2 shows cells stimulated with anti-IgM. The
integrated optical density values for EGR-1 protein in control Ig and
anti-IgM-treated BKS-2 cells were 7.83 and 2.07, respectively. Equal
loading of protein can be visualized by similar intensities of Ig heavy
chain band in both lanes. Results from a representative experiment are
shown.
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number of control studies were performed to be certain that the
effects of the antisense Egr-1 oligomers were specific. First, we
tested if the antisense and nonsense oligomers were mitogenic
to normal B lymphocytes. As shown in Fig. 5A, these oligonu-
cleotides did not induce nonspecific growth in splenic B lym-
phocytes, whereas in the same experiment two CpG-containing
oligomers (1d and 3Db), which were known to be mitogenic for
normal B lymphocytes (37), induced a strong proliferation re-
sponse. Second, both 1d and 3Db oligomers did not inhibit the
growth of BKS-2 cells but mildly enhanced the growth response
(Fig. 5A). Consistent with a slight positive effect on BKS-2
growth, these two oligomers also enhanced Egr-1 expression in
BKS-2 cells at 30 and 60 min after stimulation, which declined
subsequently (Fig. 5B). Third, antisense and nonsense oli-
gomers specific to CD72, a molecule expressed on BKS-2 cells,
or to the a-subunit of the trimeric G protein also did not inhibit
the growth of BKS-2 cells.3
Antisense Egr-1 Oligomer Induces Apoptosis in BKS-2
Cells—Experiments were carried out to examine whether an-
tisense Egr-1 oligomer treatment blocks only cell cycle progres-
sion or if it indeed causes cell death by apoptosis. In this
experiment, BKS-2 cells were cultured with either antisense or
nonsense oligomers for 24 h and then the cells were stained for
apoptosis using Hoechst 33342 and Merocyanine 540 as de-
scribed under “Materials and Methods.” The results shown in
Fig. 6B indicated that majority of BKS-2 cells (81% of the cells
were in gates R3, R4, and R5 that detect MC540 high cells)
treated with antisense oligomer undergo apoptosis. On the
other hand, most of the nonsense oligomer-treated cells were in
gate R2 (47%), which detects cycling cells that are viable (Fig.
6A), and this is similar to control Ig-treated BKS-2 cells (R2 5
45%; Fig. 6C). Induction of apoptosis caused by anti-IgM Ab
treatment in BKS-2 cells was shown in Fig. 6D, and the num-
ber of cells undergoing apoptosis in this group (78% in gates R3,
R4, and R5) was comparable to the proportion of cell death
caused by antisense oligomer. These results imply the signifi-
cance of expression of Egr-1 in the survival of BKS-2 cells.
BKS-2 Mutant Cell Line 1.B5 Is Resistant to Anti-IgM-in-
duced Growth Inhibition—We have isolated several independ-
ent mutants of BKS-2 that are resistant to anti-IgM-induced
growth inhibition.2 One such mutant, namely 1.B5, was used in
this study. Ligation of BCR by anti-IgM Ab causes growth
inhibition and subsequent apoptotic cell death in BKS-2 cells
(31). In contrast to the parental BKS-2 cells, 1.B5 mutant cells
are completely resistant to the growth inhibitory effect of anti-
IgM, as measured by [3H]thymidine incorporation (Table I).
Even immobilized anti-IgM Ab, which are known to cause
strong growth inhibition in wild type BKS-2 cells due to effec-
tive cross-linking (32, 34), failed to affect the growth of 1.B5
cells demonstrating that 1.B5 cells are completely resistant to
the growth inhibitory signal delivered via BCR.
Up-regulation of Egr-1 mRNA Expression in a BKS-2 Mutant
Cell Line, 1.B5—To examine whether anti-IgM-resistant phe-
notype of 1.B5 cells correlates with the expression of Egr-1, we
performed Northern analysis using total RNA isolated from
1.B5 cells stimulated with anti-IgM for various time intervals.
In contrast to wild type BKS-2 cells, 1.B5 mutants exhibit a
3 V. Ramiya, S. Muthukkumar, and S. Bondada, unpublished
observations.
FIG. 4. Antisense Egr-1 oligomer induces growth inhibition in
BKS-2 cells. BKS-2 cells (2 3 104/well) were cultured with the indi-
cated concentrations of nonsense or antisense Egr-1 oligomers for 48 h.
Cells were pulsed with [3H]thymidine during the last 4 h culture. Data
points indicate mean counts/min 6 S.E. of triplicate cultures from a
representative experiment. The first point indicating 0.0001 mM is re-
ally with no oligomer, but was given this value since log scale does not
allow a zero value. This experiment was repeated five times with
similar outcomes.
FIG. 5. Effects of CpG-containing oligomers on BKS-2 and nor-
mal B cell growth. A, normal DBA/2 mouse derived splenic B cells
(2 3 105) and BKS-2 (2 3 104/well) were cultured with varying amounts
of the CpG-containing oligomers 1D and 3Db as described under “Ma-
terials and Methods.” The normal B cells were also cultured with
indicated concentrations of antisense and nonsense Egr-1-specific oli-
gomers. Growth was monitored by [3H]thymidine incorporation at 48 h
as described before. B, the 3Db oligomer induces Egr-1 expression in
BKS-2 cells. The BKS-2 cells were cultured with 1.0 mM 3Db oligomer
for various time periods as indicated. The cells were then harvested,
and RNA was isolated and analyzed by Northern blot using either the
Egr-1 or the GAPDH cDNA probe. The first point indicating 0.0001 mM
is really with no oligomer, but was given this value since log scale does
not allow a zero value.
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reduced level of constitutive expression of Egr-1 mRNA (Fig. 7).
Thus densitometry analysis of the Egr-1 and GAPDH bands in
Figs. 1 and 6 showed that the ratio of Egr-1 to GAPDH in the
untreated wild type BKS-2 cells (lane 1 in Fig. 1) was 1.4:1.0
and 0.26:1.0 in the mutant 1.B5 cells (lane 1 in Fig. 7). Inter-
estingly, a marked increase in the expression Egr-1 message
was observed in 1.B5 cells as early as 30 min after stimulation
with anti-IgM (lane 2). Although a gradual decline in the mes-
sage was noticed in 1.B5 cells treated with anti-IgM for 1 and
3 h (lanes 3 and 4), the levels were significantly higher than the
untreated cells (lane 1). However, at 24 h after anti-IgM stim-
ulation, the Egr-1 message expression returned to the basal
level (lane 5) as in untreated cells. These results indicate a
strong correlation between Egr-1 expression and the nature of
signal (positive versus negative) transduced through antigen
receptor on B lymphocytes. Thus, the continued proliferation of
the 1.B5 cells in the presence of anti-IgM is likely to be due to
the sustained expression of Egr-1 gene.
DISCUSSION
In this report, BKS-2 lymphoma cells were used as a model
to study the role of Egr-1 in the induction of apoptosis caused
by BCR-mediated signals. The BKS-2 cells undergo apoptosis
upon signaling through BCR (31–35), a cellular response that
mimics the process of deletion of self-reactive immature B cells
during negative selection. Our data showed that the BKS-2
cells expressed Egr-1 constitutively and that signaling through
BCR inhibited Egr-1 expression in BKS-2 cells both at message
and protein levels. This reduction in Egr-1 expression appeared
to be causally related to the subsequent induction of apoptosis
response to BCR cross-linking because specific blocking of
Egr-1 expression in these cells using antisense oligomer also
caused apoptosis. The effects of the Egr-1 antisense oligomers
were specific, since several other oligonucleotides (a nonsense
oligomer, two pairs of oligomers specific to two other cellular
proteins and two CpG-containing oligomers proven to be mito-
genic to B cells) failed to inhibit the growth of BKS-2 cells like
the Egr-1 antisense oligomer. These data strongly indicate that
Egr-1 expression is crucial for the survival of BKS-2 cells.
The association of Egr-1 down-regulation with apoptotic sig-
nal is consistent with the observation that, in many cell types,
this gene is induced by growth stimulatory agents (10–14).
Similar growth-associated induction of Egr-1 has also been
reported in mature B lymphocytes after stimulation through
BCR (27). Although down-regulation of Egr-1 expression has
not been shown to be involved in apoptosis of any cell types
previously, two of us have recently reported that a melanoma
cell line, A375-C6, stably transfected with a dominant negative
construct of Egr-1 is highly sensitive to interleukin-1-induced
growth arrest (41). Similarly, transfection of human epithelial
tumor cell line, SQ-20B with Egr-1 dominant negative con-
struct prevented the onset of S phase and reduced the survival
of these cells exposed to ionizing radiation (44). Studies on
mouse fibroblast NIH 3T3 cells also have indicated that Egr-1
may confer resistance to growth inhibition caused by ultravio-
let radiation (45). Even though the mechanistic basis of protec-
tive function of Egr-1 in these cells is not known, it has been
postulated that EGR-1 protein may regulate genes such as
metallothionein-IIa and Ras, which have protective functions
and whose promoters also contain EGR-1 binding sites (46, 47).
In particular, Ras has been shown to have a critical role in
transmission of growth signals for various cell types including
mature B cells (5, 25, 30). It is provocative that expression of
dominant negative Ras inhibits Egr-1 expression in normal B
cells, while Ras promoter contains an EGR-1-specific binding
site (25). In contrast, expression of dominant negative ras did
not affect the negative selection of thymocytes (48). This issue
has not yet been examined for B cell apoptosis but if the same
rules apply, then Egr-1 expression may be independent of Ras
in immature B cells. Alternatively, ras may be important for B
cell apoptotic response by its ability to influence Egr-1 expres-
sion. Thus far, no studies exist that directly examine the role of
FIG. 6. Flow-cytometric analysis of apoptosis induced by anti-
sense Egr-1 oligomer in BKS-2 cells. BKS-2 cells (1 3 106/ml) were
cultured with 10 mM nonsense or antisense Egr-1 oligomers for 24 h.
Other groups of cells were stimulated with 10 mg/ml anti-IgM Ab or
control Ig. Cells were then stained with Hoechst and Merocyanin dyes
and analyzed by flow-cytometry as described under “Materials and
Methods.” The results are shown as nonsense oligomer-treated cells (A),
antisense Egr-1 oligomer-treated cells (B), control Ig-stimulated cells
(C), and anti-IgM-treated cells (D). This method of staining distin-
guishes five different stages of cells and they are denoted as R1: viable
resting cells, 2n DNA and MC540 dull; R2: viable cycling cells, .2n and
MC540 dull; R3: resting cells undergoing apoptosis, 2n and MC540
bright; R4: cycling cells undergoing apoptosis, .2n and MC540 bright;
and R5: cells that moved into later stages of apoptosis become Hoechst
33342 dull, as their DNA is fragmented. The fraction of apoptotic cells
in any sample is represented by the sum of percentages of cells in each
of the gates R3, R4 and R5. The results from one of two similar exper-
iments are shown.
TABLE I
BKS-2-derived 1.B5 mutant cell line is resistant to
anti-IgM-induced growth inhibition
BKS-2 and 1.B5 cells (2 3 104) were cultured for 48 h, and [3H]thy-
midine incorporation was measured in the last 4 h of culture. Control Ig
and soluble anti-IgM were used at 5 mg/ml, and Sepharose-coupled
anti-IgM (1 mg of Ab/ml of beads) was used at 1% final concentration.
Stimulation
[3H]Thymidine incorporation
BKS-2 1-B5
cpm 6 S.E.
None 42,090 6 362 62,093 6 1,357
Control Ig 43,732 6 965 65,221 6 2,018
Soluble anti-IgM 3,735 6 244 66,399 6 1,176
Immobilized anti-IgM 1,073 6 51 56,444 6 183
FIG. 7. Anti-IgM stimulation causes up-regulation of Egr-1 ex-
pression in 1.B5 cells. 1.B5 mutant cells were stimulated with anti-
IgM (10 mg/ml) for various intervals of time as indicated. Then the cells
were processed for Northern analysis with Egr-1 or GAPDH cDNA
probe. The same blot was later analyzed for the expression of GAPDH.
The times of exposure to x-ray film for the Egr-1 blot and GAPDH blot
were 24 h and 6 h, respectively. Results from one of four independent
experiments are shown.
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EGR-1 protein on ras gene expression or the requirement for
ras in anti-IgM-induced B cell apoptosis.
In contrast to its role as a gene required for cell growth,
recently Egr-1 was found to be one of the factors required for
thapsigargin and ionizing radiation-induced apoptosis in
A375-C6 melanoma cell line (49, 50). In this cell line, blockade
of Egr-1 expression with a dominant negative construct or
antisense probes inhibited apoptosis induced by calcium eleva-
tion or ionizing radiation. It is conceivable that in A375-C6 cells
Egr-1 up-regulates nur77 or a related gene that has been
shown to be required for apoptosis in certain cell types (18).
Dual roles for Egr-1 resemble those for c-myc, which also pro-
tects as well as promotes apoptosis (51). In particular, B cell
lines have been shown to be growth-inhibited when c-myc lev-
els fall below background levels, and the growth is restored by
constitutive expression of c-myc (51). It is conceivable that the
growth inhibition and apoptosis of BKS-2 cells in response to
reduction in Egr-1 levels is due to an inhibition of c-myc
expression.
Egr-1 is neither constitutively expressed nor up-regulated by
BCR crosslinking either in neonatal B cells or in WEHI-231-
like immature B cell lymphoma cells (7, 29) in which the
response to anti-IgM stimulation is growth inhibition and ap-
optosis. However, the lipopolysaccharide-mediated protection
of WEHI-231 cells from anti-IgM-induced apoptosis is associ-
ated with Egr-1 induction (52). Thus, the apparent relation
between Egr-1 expression and B cell growth can be demon-
strated with both B cell lymphoma cell lines and normal B cells
of different maturation stages. Hence, the differential regula-
tion of Egr-1 expression in mature and immature B lympho-
cytes is likely to be due to a difference in early signaling events
between these cells.
The mutant cell line, 1.B5, was refractory to anti-IgM-in-
duced growth inhibitory signals and showed a lower level of
constitutive expression of Egr-1 (Figs. 1 and 7) in contrast to
the wild type BKS-2 cells. Interestingly, these mutant BKS-2
cells behaved like normal mature B cells in that signaling
through BCR caused a strong induction of Egr-1 message (27).
Anti-IgM-induced early signaling events are nearly identical in
the immature B cell lines, WEHI-231 and BKS-2 cells2 that
undergo apoptosis and in the normal mature B lymphocytes
that respond by entering into cell cycle (5). In both immature B
cell lines and mature B cells, cross-linking of BCR induces
activation of Src family (Blk, Lyn) as well as non-Src family
protein-tyrosine kinases (5). In both cell types, expression of
c-myc is initially elevated but the subsequent down-regulation
is unique to each cell type (51). Studies presented here suggest
that the regulation of Egr-1 gene dramatically differs between
the mature and immature B cells, with the former exhibiting
an up-regulation while the latter respond by down-regulation
of Egr-1. At present, both protein kinase C pathway and the
Ras-MAP kinase cascade have been shown to induce elevation
of Egr-1 gene (7, 30). The wild type and mutant BKS-2 cells
along with normal mature B cells provide a unique model
system to define the early signaling events that lead to differ-
ential regulation of Egr-1 gene. Our preliminary studies with
BKS-2 and the mutant 1.B5 cells suggest that activation of Blk
and Lyn protein-tyrosine kinases may not be required for up-
regulation of Egr-1 expression.2
Although some of the recent reports clarify the role of Egr-1
in BCR-mediated activation of mature B cells (25, 26), its role
in the negative growth response is poorly understood. It is
possible that Egr-1-mediated control of the negative growth
response in BKS-2 cells might be exerted at the transcriptional
level by regulating the expression of certain key growth re-
sponse genes. Indeed, EGR-1 has been shown to be a positive
activator of transcription by binding to GC-rich consensus DNA
sequences of many target genes involved in positive regulation
of cell growth, but the effect of Egr-1 on the expression of the
survival genes belonging to the Bcl-2-Bcl-xL family has not yet
been investigated (53). We have observed that rapamycin-in-
duced apoptosis of BKS-2 cells (33) is associated with down-
regulation Egr-1 as well as Bcl-2 gene products.4 Therefore, we
are currently evaluating the effect of anti-IgM and antisense
Egr-1 oligomers on the expression of Bcl-2 gene family in
BKS-2 cells.
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